|
Ipilimumab para pacientes con melanoma metastásico [Ipilimumab for patients with metastatic melanoma] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Rey-Ares L, Caccavo F |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Rey-Ares L, Caccavo F. Ipilimumab para pacientes con melanoma metastásico. [Ipilimumab for patients with metastatic melanoma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 265. 2012 Authors' objectives To assess the available evidence on the efficacy, safety and issues related to coverage policies for the use of ipilimumab in patients with metastatic melanoma. Authors' conclusions The ipilimumab use for the treatment of metastatic melanoma, both as first and second line therapy should be assessed considering that, currently, there is no standard treatment for this disease, although the use of dacarbazine is widespread. Even though the evidence found comes from RCTs, none of the studies directly compared ipilimumab versus dacarbazine or placebo. Ipilimumab as monotherapy proved to be better than the gp100 vaccine and in combination with dacarbazine, proved to be better than dacarbazine as monotherapy. Although its cost-effectiveness has not been evaluated, it should be considered that the cost of the ipilimumab therapy is approximately 40 times higher than that of dacarbazine therapy. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Agents; Humans; Melanoma; Neoplasm Metastasis Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000299 Date abstract record published 31/01/2014 |
|
|
|